Psychopharmacology and Psychiatry Updates podcast

Breaking Down the TRAILBLAZER-ALZ 2 Trial

0:00
10:27
Recuar 15 segundos
Avançar 15 segundos

In this episode, we explore donanemab, a groundbreaking monoclonal antibody treatment for Alzheimer's disease. We discuss its efficacy in reducing beta-amyloid plaques, unique treatment duration protocol, and safety considerations. Could this time-limited treatment approach revolutionize how we manage Alzheimer's progression?

Faculty: Scott Beach, M.D.
Host: Richard Seeber, M.D.

Mais episódios de "Psychopharmacology and Psychiatry Updates"